Navigation Links
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Date:8/19/2007

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into agreements to sell 2.0 million shares of common stock and warrants to purchase 0.4 million shares of common stock, at a purchase price of $3.785 per unit. The five-year warrants will be exercisable at any time after the six month anniversary of issuance at an exercise price of $3.948 per share.

The securities in this transaction were offered by Emisphere pursuant to an effective shelf registration statement and a registration statement filed pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended.

ThinkEquity Partners LLC acted as sole placement agent, and WBB Securities LLC acted as financial consultant. Proceeds from the offering will be used by Emisphere for general corporate purposes, including further development of its lead clinical programs. The transaction is expected to close on or about August 22, 2007, subject to the satisfaction of customary closing conditions.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

The offer is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. When available, a final prospectus can be obtained from Emisphere Technologies, Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591; telephone, (914) 785-4717 or from the U.S. Securities and Exchange Commission at http://www.sec.gov.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com.


'/>"/>
SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Orlando, FL (PRWEB) , ... February 21, 2017 ... ... that enables healthcare organizations to build connected digital health applications, announced a partnership ... will enable users to seamlessly connect to many clinical systems while keeping data ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... biotech research and development (R&D), today announced the establishment of Genedata Limited as ... Director Kevin Teburi, a recognized expert in life science informatics. Creating the UK ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of stem ... in multiple areas of medicine, due to their differentiating characteristics. Stem cells are unique ... the ability to be induced to become tissue or organic-specific cells with special functions. ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
Breaking Biology News(10 mins):